Also trades as: IGAP (NASDAQ) · $vol 0M
GCTK NASDAQ
GlucoTrack, Inc.
1W: -33.5%
1M: -65.7%
3M: -74.6%
YTD: -97.9%
1Y: -98.7%
3Y: -100.0%
5Y: -100.0%
$1.21
-0.20 (-14.18%)
Weekly Expected Move ±25.9%
$1
$1
$1
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.0M
52W Range1.16-136.29
Volume291,411
Avg Volume861,803
Beta0.62
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOErik Emerson
Employees15
SectorHealthcare
IndustryMedical - Devices
IPO Date2013-04-25
Websiteglucotrack.com
301 Route 17 North
Rutherford, NJ 07070
US
Rutherford, NJ 07070
US
972 8 675 7878
About GlucoTrack, Inc.
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
Latest News
Glucotrack prices $3.1M public offering
Glucotrack announces $11.5M financing
Glucotrack announces 1-for-15 reverse stock split
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Balo Andrew K | A-Award | 1,285 | — | 2025-10-03 |
| Balo Andrew K | A-Award | 4,055 | $7.40 | 2025-10-03 |
| Malave Luis | A-Award | 463 | — | 2025-10-03 |
| Malave Luis | A-Award | 4,055 | $7.40 | 2025-10-03 |
| Carter Erin Catherin | A-Award | 4,055 | $7.40 | 2025-10-03 |